机构:[1]Department of Breast Surgery, School of Medicine, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.四川省人民医院[2]Department of Health Management & Institute of Health Management, School of Medicine, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.四川省人民医院[3]State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, China.四川大学华西医院
第一作者机构:[1]Department of Breast Surgery, School of Medicine, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.
共同第一作者:
通讯作者:
推荐引用方式(GB/T 7714):
Li Juan,Liang Yu,Zhou Shijie,et al.UCHL1 contributes to insensitivity to endocrine therapy in triple-negative breast cancer by deubiquitinating and stabilizing KLF5[J].BREAST CANCER RESEARCH.2024,26(1):44.doi:10.1186/s13058-024-01800-1.
APA:
Li Juan,Liang Yu,Zhou Shijie,Chen Jie&Wu Chihua.(2024).UCHL1 contributes to insensitivity to endocrine therapy in triple-negative breast cancer by deubiquitinating and stabilizing KLF5.BREAST CANCER RESEARCH,26,(1)
MLA:
Li Juan,et al."UCHL1 contributes to insensitivity to endocrine therapy in triple-negative breast cancer by deubiquitinating and stabilizing KLF5".BREAST CANCER RESEARCH 26..1(2024):44